Literature DB >> 28344886

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.

Nan Chen1, Aurore Morello1, Zachary Tano2, Prasad S Adusumilli1.   

Abstract

PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.

Entities:  

Keywords:  Adoptive T-cell therapy; PD-1 blockade; breast cancer; immunosuppression; lung cancer; mesothelioma; tumor microenvironment

Year:  2016        PMID： 28344886      PMCID： PMC5353939          DOI： 10.1080/2162402X.2016.1273302

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  7 in total

1.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Authors:  Prasad S Adusumilli; Leonid Cherkassky; Jonathan Villena-Vargas; Christos Colovos; Elliot Servais; Jason Plotkin; David R Jones; Michel Sadelain
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

2.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

Authors:  Xiaojun Liu; Raghuveer Ranganathan; Shuguang Jiang; Chongyun Fang; Jing Sun; Soyeon Kim; Kheng Newick; Albert Lo; Carl H June; Yangbing Zhao; Edmund K Moon
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

3.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

Review 4.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 5.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 6.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.

Authors:  Aurore Morello; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Discov       Date:  2015-10-26       Impact factor: 39.397

7.  CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.

Authors:  Levi J Rupp; Kathrin Schumann; Kole T Roybal; Rachel E Gate; Chun J Ye; Wendell A Lim; Alexander Marson
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379
  7 in total
  54 in total

1.  Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Authors:  Mark B Geyer; Isabelle Rivière; Brigitte Sénéchal; Xiuyan Wang; Yongzeng Wang; Terence J Purdon; Meier Hsu; Sean M Devlin; M Lia Palomba; Elizabeth Halton; Yvette Bernal; Dayenne G van Leeuwen; Michel Sadelain; Jae H Park; Renier J Brentjens
Journal:  JCI Insight       Date:  2019-04-02

Review 2.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

Review 3.  CAR T-cell therapy for pancreatic cancer.

Authors:  Carl J DeSelm; Zachary E Tano; Anna M Varghese; Prasad S Adusumilli
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 3.454

4.  Novel immunotherapy clinical trials in malignant pleural mesothelioma.

Authors:  Zachary E Tano; Navin K Chintala; Xiaoyu Li; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2017-06

Review 5.  Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.

Authors:  Juanjuan Zhao; Meirong Wu; Zhifeng Li; Sheng Su; Yin Wen; Litian Zhang; Yuhua Li
Journal:  Ann Hematol       Date:  2020-05-09       Impact factor: 3.673

6.  Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.

Authors:  Zhao Zhang; Jun Jiang; Xiaodong Wu; Mengyao Zhang; Dan Luo; Renyu Zhang; Shiyou Li; Youwen He; Huijie Bian; Zhinan Chen
Journal:  Front Med       Date:  2019-02-05       Impact factor: 4.592

7.  Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies.

Authors:  Theodore L Roth; P Jonathan Li; Franziska Blaeschke; Jasper F Nies; Ryan Apathy; Cody Mowery; Ruby Yu; Michelle L T Nguyen; Youjin Lee; Anna Truong; Joseph Hiatt; David Wu; David N Nguyen; Daniel Goodman; Jeffrey A Bluestone; Chun Jimmie Ye; Kole Roybal; Eric Shifrut; Alexander Marson
Journal:  Cell       Date:  2020-04-16       Impact factor: 41.582

Review 8.  Solid Tumors Challenges and New Insights of CAR T Cell Engineering.

Authors:  Safa Tahmasebi; Reza Elahi; Abdolreza Esmaeilzadeh
Journal:  Stem Cell Rev Rep       Date:  2019-10       Impact factor: 5.739

Review 9.  Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.

Authors:  Emre Balta; Guido H Wabnitz; Yvonne Samstag
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

10.  HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo.

Authors:  Zhengtao Jiang; Huitong Liang; Hanyu Pan; Yue Liang; Hua Wang; Xinyi Yang; Panpan Lu; Xiao Zhang; Jinlong Yang; Dengji Zhang; Xiaoting Shen; Jing Wang; Zhiming Liang; Qinru Lin; Yanan Wang; Lin Zhao; Yangcheng Zhong; Hongzhou Lu; Huanzhang Zhu
Journal:  Front Microbiol       Date:  2021-07-06       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.